Current and novel therapeutic strategies in celiac disease

References

• Ludvigsson JF, Leffler DA, Bai JC, et al. The Oslo definitions for coeliac disease and related terms. Gut. 2013;62:43–52.
   PubMed Web of Science ®Google Scholar
• Rubio-Tapia A, Hill ID, Kelly CP, et al. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol. 2013;108:656–676; quiz 677.
   Web of Science ®Google Scholar
• Rostom A, Murray JA, Kagnoff MF. American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease. Gastroenterology. 2006;131:1981–2002.
   PubMed Web of Science ®Google Scholar
• Husby S, Koletzko S, Korponay-Szabo IR, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr. 2012;54:136–160.
   PubMed Web of Science ®Google Scholar
• Bai JC, Fried M, Corazza GR, et al. World Gastroenterology Organisation global guidelines on celiac disease. J Clin Gastroenterol. 2013;47:121–126.
   PubMed Web of Science ®Google Scholar
• Roshan B, Leffler DA, Jamma S, et al. The incidence and clinical spectrum of refractory celiac disease in a north american referral center. Am J Gastroenterol. 2011;106:923–928.
   PubMed Web of Science ®Google Scholar
• Newnham ED, Shepherd SJ, Strauss BJ, et al. Adherence to the gluten-free diet can achieve the therapeutic goals in almost all patients with coeliac disease: A five-year longitudinal study from diagnosis. J Gastroenterol Hepatol. 2016;31(2):342–349.
   PubMed Web of Science ®Google Scholar
• Schmitz F, Tjon JML, Lai Y, et al. Identification of a potential physiological precursor of aberrant cells in refractory coeliac disease type II. Gut. 2013;62:509–519.
   PubMed Web of Science ®Google Scholar
• Patey-Mariaud De Serre N, Cellier C, Jabri B, et al. Distinction between coeliac disease and refractory sprue: a simple immunohistochemical method. Histopathology. 2000;37:70–77.
   PubMed Web of Science ®Google Scholar
• Rubio-Tapia A, Kelly DG, Lahr BD, et al. Clinical staging and survival in refractory celiac disease: a single center experience. Gastroenterology. 2009;136:99–107;quiz 352–353.
   PubMed Web of Science ®Google Scholar
• Rubio-Tapia A, Murray JA. Classification and management of refractory coeliac disease. Gut. 2010;59:547–557.
   PubMed Web of Science ®Google Scholar
• Sollid LM. Coeliac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol. 2002;2:647–655.
   PubMed Web of Science ®Google Scholar
• Menard S, Lebreton C, Schumann M, et al. Paracellular versus transcellular intestinal permeability to gliadin peptides in active celiac disease. Am J Pathol. 2012;180:608–615.
   PubMed Web of Science ®Google Scholar
• Rauhavirta T, Qiao SW, Jiang Z, et al. Epithelial transport and deamidation of gliadin peptides: a role for coeliac disease patient immunoglobulin A. Clin Exp Immunol. 2011;164:127–136.
   PubMed Web of Science ®Google Scholar
• Matysiak-Budnik T, Moura IC, Arcos-Fajardo M, et al. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. J Exp Med. 2008;205:143–154.
   PubMed Web of Science ®Google Scholar
• Di Sabatino A, Ciccocioppo R, Cupelli F, et al. Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease. Gut. 2006;55:469–477.
   PubMed Web of Science ®Google Scholar
• Manavalan JS, Hernandez L, Shah JG, et al. Serum cytokine elevations in celiac disease: association with disease presentation. Hum Immunol. 2010;71:50–57.
   PubMed Web of Science ®Google Scholar
• Gross S, van Wanrooij RL, Nijeboer P, et al. Differential IL-13 production by small intestinal leukocytes in active coeliac disease versus refractory coeliac disease. Mediators Inflamm. 2013;2013:939047.
   PubMed Web of Science ®Google Scholar
• Mention JJ, Ben Ahmed M, Begue B, et al. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology. 2003;125:730–745.
   PubMed Web of Science ®Google Scholar
• Malamut G, El Machhour R, Montcuquet N, et al. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. J Clin Invest. 2010;120:2131–2143.
   PubMed Web of Science ®Google Scholar
• van Leeuwen MA, Lindenbergh-Kortleve DJ, Raatgeep HC, et al. Increased production of interleukin-21, but not interleukin-17A, in the small intestine characterizes pediatric celiac disease. Mucosal Immunol. 2013;6:1202–1213.
   PubMed Web of Science ®Google Scholar
• Sarra M, Cupi ML, Monteleone I, et al. IL-15 positively regulates IL-21 production in celiac disease mucosa. Mucosal Immunol. 2013;6:244–255.
   PubMed Web of Science ®Google Scholar
• Di Sabatino A, Rovedatti L, Vetrano S, et al. Involvement of CD40-CD40 ligand in uncomplicated and refractory celiac disease. Am J Gastroenterol. 2011;106:519–527.
   PubMed Web of Science ®Google Scholar
• King AL, Moodie SJ, Fraser JS, et al. CTLA-4/CD28 gene region is associated with genetic susceptibility to coeliac disease in UK families. J Med Genet. 2002;39:51–54.
   PubMed Web of Science ®Google Scholar
• Stuber E, Buschenfeld A, Luttges J, et al. The expression of OX40 in immunologically mediated diseases of the gastrointestinal tract (celiac disease, Crohn’s disease, ulcerative colitis). Eur J Clin Invest. 2000;30:594–599.
   PubMed Web of Science ®Google Scholar
• Tjon JM-L, Kooy-Winkelaar YMC, Tack GJ, et al. DNAM-1 mediates epithelial cell-specific cytotoxicity of aberrant intraepithelial lymphocyte lines from refractory celiac disease type II patients. J Immunol. 2011;186:6304–6312.
   PubMed Web of Science ®Google Scholar
• Di Sabatino A, Giuffrida P, Vanoli A, et al. Increase in neuroendocrine cells in the duodenal mucosa of patients with refractory celiac disease. Am J Gastroenterol. 2014;109:258–269.
   PubMed Web of Science ®Google Scholar
• Colombo G, Buffa R, Bardella MT, et al. Anti-inflammatory effects of alpha-melanocyte-stimulating hormone in celiac intestinal mucosa. Neuroimmunomodulation. 2002;10:208–216.
   PubMed Web of Science ®Google Scholar
• Akobeng AK, Thomas AG. Systematic review: tolerable amount of gluten for people with coeliac disease. Aliment Pharmacol Ther. 2008;27:1044–1052.
   PubMed Web of Science ®Google Scholar
• Bash E. Standard for foods for special dietary use for persons intolerant to gluten CODEX STAN 118-1979 Adopted in 1979. Amendment: 1983 and 2015. Revision: 2008. PhD Propos. 2015;1. doi:10.1017/CBO9781107415324.004.
   Google Scholar
• Abdulkarim AS, Burgart LJ, See J, et al. Etiology of nonresponsive celiac disease: results of a systematic approach. Am J Gastroenterol. 2002;97:2016–2021.
   PubMed Web of Science ®Google Scholar
• Leffler DA, Dennis M, Hyett B, et al. Etiologies and predictors of diagnosis in nonresponsive celiac disease. Clin Gastroenterol Hepatol. 2007;5:445–450.
   PubMed Web of Science ®Google Scholar
• Thompson T, Simpson S. A comparison of gluten levels in labeled gluten-free and certified gluten-free foods sold in the United States. Eur J Clin Nutr. 2015;69:143–146.
   PubMed Web of Science ®Google Scholar
• Oza SS, Akbari M, Kelly CP, et al. Socioeconomic risk factors for celiac disease burden and symptoms. J Clin Gastroenterol. 2016;50:307–312.
   PubMed Web of Science ®Google Scholar
• Shah S, Akbari M, Vanga R, et al. Patient perception of treatment burden is high in celiac disease compared with other common conditions. Am J Gastroenterol. 2014;109:1304–1311.
   PubMed Web of Science ®Google Scholar
• MacCulloch K, Rashid M. Factors affecting adherence to a gluten-free diet in children with celiac disease. Paediatr Child Health. 2014;19:305–309.
   PubMed Web of Science ®Google Scholar
• Shepherd SJ, Gibson PR. Nutritional inadequacies of the gluten-free diet in both recently-diagnosed and long-term patients with coeliac disease. J Hum Nutr Diet. 2013;26:349–358.
   PubMed Web of Science ®Google Scholar
• Thompson T, Dennis M, Higgins LA, et al. Gluten-free diet survey: are Americans with coeliac disease consuming recommended amounts of fibre, iron, calcium and grain foods? J Hum Nutr Diet. 2005;18:163–169.
   PubMed Web of Science ®Google Scholar
• Kabbani TA, Goldberg A, Kelly CP, et al. Body mass index and the risk of obesity in coeliac disease treated with the gluten-free diet. Aliment Pharmacol Ther. 2012;35:723–729.
   PubMed Web of Science ®Google Scholar
• Valletta E, Fornaro M, Cipolli M, et al. Celiac disease and obesity: need for nutritional follow-up after diagnosis. Eur J Clin Nutr. 2010;64:1371–1372.
   PubMed Web of Science ®Google Scholar
• Olaussen RW, Lovik A, Tollefsen S, et al. Effect of elemental diet on mucosal immunopathology and clinical symptoms in type 1 refractory celiac disease. Clin Gastroenterol Hepatol. 2005;3:875–885.
   PubMed Web of Science ®Google Scholar
• van den Broeck HC, van Herpen TW, Schuit C, et al. Removing celiac disease-related gluten proteins from bread wheat while retaining technological properties: a study with Chinese Spring deletion lines. BMC Plant Biol. 2009;9:41.
   PubMed Web of Science ®Google Scholar
• Spaenij-Dekking L, Kooy-Winkelaar Y, van Veelen P, et al. Natural variation in toxicity of wheat: potential for selection of nontoxic varieties for celiac disease patients. Gastroenterology. 2005;129:797–806.
   PubMed Web of Science ®Google Scholar
• Gil-Humanes J, Piston F, Altamirano-Fortoul R, et al. Reduced-gliadin wheat bread: an alternative to the gluten-free diet for consumers suffering gluten-related pathologies. PLoS One. 2014;9:e90898.
   Google Scholar
• Shan L, Molberg O, Parrot I, et al. Structural basis for gluten intolerance in celiac sprue. Science. 2002;297:2275–2279.
   PubMed Web of Science ®Google Scholar
• Gass J, Khosla C. Prolyl endopeptidases. Cell Mol Life Sci. 2007;64:345–355.
   PubMed Web of Science ®Google Scholar
• Mitea C, Havenaar R, Drijfhout JW, et al. Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease. Gut. 2008;57:25–32.
   PubMed Web of Science ®Google Scholar
• Shan L, Marti T, Sollid LM, et al. Comparative biochemical analysis of three bacterial prolyl endopeptidases: implications for coeliac sprue. Biochem J. 2004;383:311–318.
   PubMed Web of Science ®Google Scholar
• Tack GJ, van de Water JMW, Bruins MJ, et al. Consumption of gluten with gluten-degrading enzyme by celiac patients: a pilot-study. World J Gastroenterol. 2013;19:5837–5847.
   PubMed Web of Science ®Google Scholar
• Tye-Din JA, Anderson RP, Ffrench RA, et al. The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clin Immunol. 2010;134:289–295.
   PubMed Web of Science ®Google Scholar
• Siegel M, Garber ME, Spencer AG, et al. Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials. Dig Dis Sci. 2012;57:440–450.
   PubMed Web of Science ®Google Scholar
• Lahdeaho ML, Kaukinen K, Laurila K, et al. Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease. Gastroenterology. 2014;146:1649–1658.
   PubMed Web of Science ®Google Scholar
• McCarville JL, Nisemblat Y, Galipeau HJ, et al. BL-7010 demonstrates specific binding to gliadin and reduces gluten-associated pathology in a chronic mouse model of gliadin sensitivity. PLoS One. 2014;9:e109972.
   Google Scholar
• Gujral N, Lobenberg R, Suresh M, et al. In-vitro and in-vivo binding activity of chicken egg yolk immunoglobulin Y (IgY) against gliadin in food matrix. J Agric Food Chem. 2012;60:3166–3172.
   PubMed Web of Science ®Google Scholar
• Gujral N, Suh JW, Sunwoo HH. Effect of anti-gliadin IgY antibody on epithelial intestinal integrity and inflammatory response induced by gliadin. BMC Immunol. 2015;16:41.
   PubMed Web of Science ®Google Scholar
• Drago S, El Asmar R, Di Pierro M, et al. Gliadin, zonulin and gut permeability: effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol. 2006;41:408–419.
   PubMed Web of Science ®Google Scholar
• Clemente MG, De Virgiliis S, Kang JS, et al. Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function. Gut. 2003;52:218–223.
   PubMed Web of Science ®Google Scholar
• Paterson BM, Lammers KM, Arrieta MC, et al. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther. 2007;26:757–766.
   PubMed Web of Science ®Google Scholar
• Leffler DA, Kelly CP, Abdallah HZ, et al. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am J Gastroenterol. 2012;107:1554–1562.
   PubMed Web of Science ®Google Scholar
• Kelly CP, Green PH, Murray JA, et al. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Aliment Pharmacol Ther. 2013;37:252–262.
   PubMed Web of Science ®Google Scholar
• Leffler DA, Kelly CP, Green PHR, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology. 2015;148:1311–1319e6.
   PubMed Web of Science ®Google Scholar
• Rauhavirta T, Oittinen M, Kivisto R, et al. Are transglutaminase 2 inhibitors able to reduce gliadin-induced toxicity related to celiac disease? A proof-of-concept study. J Clin Immunol. 2013;33:134–142.
   PubMed Web of Science ®Google Scholar
• Chang MS, Minaya MT, Cheng J, et al. Double-blind randomized controlled trial of rifaximin for persistent symptoms in patients with celiac disease. Dig Dis Sci. 2011;56:2939–2946.
   PubMed Web of Science ®Google Scholar
• Smecuol E, Hwang HJ, Sugai E, et al. Exploratory, randomized, double-blind, placebo-controlled study on the effects of Bifidobacterium infantis natren life start strain super strain in active celiac disease. J Clin Gastroenterol. 2013;47:139–147.
   PubMed Web of Science ®Google Scholar
• Summers RW, Elliott DE, Qadir K, et al. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2003;98:2034–2041.
   PubMed Web of Science ®Google Scholar
• Daveson AJ, Jones DM, Gaze S, et al. Effect of hookworm infection on wheat challenge in celiac disease–a randomised double-blinded placebo controlled trial. PLoS One. 2011;6:e17366.
   PubMed Web of Science ®Google Scholar
• van Gils T, Nijeboer P, van Wanrooij RL, et al. Mechanisms and management of refractory coeliac disease. Nat Rev Gastroenterol Hepatol. 2015;12:572–579.
   PubMed Web of Science ®Google Scholar
• Vivas S, Ruiz De Morales JM, Ramos F, et al. Alemtuzumab for refractory celiac disease in a patient at risk for enteropathy-associated T-cell lymphoma. N Engl J Med. 2006;354:2514–2515.
   PubMed Web of Science ®Google Scholar
• Tack GJ, Wondergem MJ, Al-Toma A, et al. Auto-SCT in refractory celiac disease type II patients unresponsive to cladribine therapy. Bone Marrow Transplant. 2011;46:840–846.
   PubMed Web of Science ®Google Scholar
• Al-toma A, Visser OJ, van Roessel HM, et al. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood. 2007;109:2243–2249.
   PubMed Web of Science ®Google Scholar
• Maurino E, Niveloni S, Chernavsky A, et al. Azathioprine in refractory sprue: results from a prospective, open-label study. Am J Gastroenterol. 2002;97:2595–2602.
   PubMed Web of Science ®Google Scholar
• Goerres MS, Meijer JW, Wahab PJ, et al. Azathioprine and prednisone combination therapy in refractory coeliac disease. Aliment Pharmacol Ther. 2003;18:487–494.
   PubMed Web of Science ®Google Scholar
• Brar P, Lee S, Lewis S, et al. Budesonide in the treatment of refractory celiac disease. Am J Gastroenterol. 2007;102:2265–2269.
   PubMed Web of Science ®Google Scholar
• Tack GJ, Verbeek WHM, Al-Toma A, et al. Evaluation of cladribine treatment in refractory celiac disease type II. World J Gastroenterol. 2011;17:506–513.
   PubMed Web of Science ®Google Scholar
• Al-Toma A, Goerres MS, Meijer JWR, et al. Cladribine therapy in refractory celiac disease with aberrant T cells. Clin Gastroenterol Hepatol. 2006;4:1322–1327; quiz 1300.
   Web of Science ®Google Scholar
• Wahab PJ, Crusius JB, Meijer JW, et al. Cyclosporin in the treatment of adults with refractory coeliac disease–an open pilot study. Aliment Pharmacol Ther. 2000;14:767–774.
   PubMed Web of Science ®Google Scholar
• Mulder CJ, Wahab PJ, Meijer JW, et al. A pilot study of recombinant human interleukin-10 in adults with refractory coeliac disease. Eur J Gastroenterol Hepatol. 2001;13:1183–1188.
   PubMed Web of Science ®Google Scholar
• Rawal N, Twaddell W, Fasano A, et al. Remission of refractory celiac disease with infliximab in a pediatric patient. ACG Case Rep J. 2015;2:121–123.
   PubMedGoogle Scholar
• Costantino G, Della Torre A, Lo Presti MA, et al. Treatment of life-threatening type I refractory coeliac disease with long-term infliximab. Dig Liver Dis. 2008;40:74–77.
   PubMedGoogle Scholar
• Gillett HR, Arnott IDR, McIntyre M, et al. Successful infliximab treatment for steroid-refractory celiac disease: a case report. Gastroenterology. 2002;122:800–805.
   PubMed Web of Science ®Google Scholar
• Jamma S, Leffler DA, Dennis M, et al. Small intestinal release mesalamine for the treatment of refractory celiac disease type I. J Clin Gastroenterol. 2011;45:30–33.
   PubMed Web of Science ®Google Scholar
• Tack GJ, van Asseldonk DP, van Wanrooij RL, et al. Tioguanine in the treatment of refractory coeliac disease–a single centre experience. Aliment Pharmacol Ther. 2012;36:274–281.
   PubMed Web of Science ®Google Scholar
• Vaidya A, Bolanos J, Berkelhammer C. Azathioprine in refractory sprue. Am J Gastroenterol. 1999;94:1967–1969.
   PubMed Web of Science ®Google Scholar
• Enns R, Lay T, Bridges R. Use of azathioprine for nongranulomatous ulcerative jejunoileitis. Can J Gastroenterol. 1997;11:503–506.
   PubMed Web of Science ®Google Scholar
• Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000;47:119–125.
   PubMed Web of Science ®Google Scholar
• Rolny P, Sigurjonsdottir HA, Remotti H, et al. Role of immunosuppressive therapy in refractory sprue-like disease. Am J Gastroenterol. 1999;94:219–225.
   PubMed Web of Science ®Google Scholar
• Karagozian R, Burakoff R. The role of mesalamine in the treatment of ulcerative colitis. Ther Clin Risk Manag. 2007;3:893–903.
   PubMedGoogle Scholar
• Shalimar, Das P, Sreenivas V, et al. Effect of addition of short course of prednisolone to gluten-free diet on mucosal epithelial cell regeneration and apoptosis in celiac disease: a pilot randomized controlled trial. Dig Dis Sci. 2012;57:3116–3125.
   PubMed Web of Science ®Google Scholar
• Daum S, Ipczynski R, Heine B, et al. Therapy with budesonide in patients with refractory sprue. Digestion. 2006;73:60–68.
   PubMed Web of Science ®Google Scholar
• Yokoyama S, Perera PY, Waldmann TA, et al. Tofacitinib, a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease. J Clin Immunol. 2013;33:586–594.
   PubMed Web of Science ®Google Scholar
• Verbeek WHM, Mulder CJJ, Zweegman S. Alemtuzumab for refractory celiac disease. N Engl J Med. 2006;355:1396–1397; author reply 1397.
   Web of Science ®Google Scholar